FDA issues two guidances to accelerate COVID-19 treatments

The US Food and Drug Administration (FDA) on Monday evening issued two guidances intended to accelerate the development of products to treat or prevent coronavirus disease (COVID-19), laying out recommendations to help companies get to the investigational new drug application (IND) stage and clinical trial design considerations for later-stage studies.